CN116528852A - 含有1-(3-氰基-1-异丙基-吲哚-5-基)吡唑-4-甲酸的稳定的口服制剂 - Google Patents

含有1-(3-氰基-1-异丙基-吲哚-5-基)吡唑-4-甲酸的稳定的口服制剂 Download PDF

Info

Publication number
CN116528852A
CN116528852A CN202180078624.3A CN202180078624A CN116528852A CN 116528852 A CN116528852 A CN 116528852A CN 202180078624 A CN202180078624 A CN 202180078624A CN 116528852 A CN116528852 A CN 116528852A
Authority
CN
China
Prior art keywords
api
formulation
oral formulation
cyano
isopropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180078624.3A
Other languages
English (en)
Chinese (zh)
Inventor
刘锡澈
李宣
尹惪溢
朴正洪
宣贤智
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xinda Biotechnology Co ltd
Original Assignee
LG Chem Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LG Chem Ltd filed Critical LG Chem Ltd
Publication of CN116528852A publication Critical patent/CN116528852A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202180078624.3A 2020-12-01 2021-11-30 含有1-(3-氰基-1-异丙基-吲哚-5-基)吡唑-4-甲酸的稳定的口服制剂 Pending CN116528852A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20200166051 2020-12-01
KR10-2020-0166051 2020-12-01
PCT/KR2021/017842 WO2022119269A1 (ko) 2020-12-01 2021-11-30 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산을 포함하는 안정한 경구용 제제

Publications (1)

Publication Number Publication Date
CN116528852A true CN116528852A (zh) 2023-08-01

Family

ID=81854222

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180078624.3A Pending CN116528852A (zh) 2020-12-01 2021-11-30 含有1-(3-氰基-1-异丙基-吲哚-5-基)吡唑-4-甲酸的稳定的口服制剂

Country Status (15)

Country Link
US (1) US20240000751A1 (https=)
EP (1) EP4257123A4 (https=)
JP (1) JP7678106B2 (https=)
KR (1) KR20220077091A (https=)
CN (1) CN116528852A (https=)
AR (1) AR124178A1 (https=)
AU (2) AU2021390901B9 (https=)
CA (1) CA3197405A1 (https=)
CL (1) CL2023001215A1 (https=)
CO (1) CO2023008265A2 (https=)
MX (1) MX2023005459A (https=)
PE (1) PE20240222A1 (https=)
TW (3) TWI896975B (https=)
WO (1) WO2022119269A1 (https=)
ZA (1) ZA202305156B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20240242A1 (es) * 2021-06-15 2024-02-16 Lg Chemical Ltd Una composicion farmaceutica que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico
AR126164A1 (es) * 2021-06-17 2023-09-27 Lg Chemical Ltd Formulación compuesta para dosificación oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102574839A (zh) * 2009-10-07 2012-07-11 株式会社Lg生命科学 有效作为黄嘌呤氧化酶抑制剂的新化合物、该化合物的制备方法和含有该化合物的药物组合物
CN103459381A (zh) * 2011-04-06 2013-12-18 株式会社Lg生命科学 1-(3-氰基-1-异丙基-吲哚-5-基)吡唑-4-甲酸晶型及其生产方法
WO2020109319A1 (en) * 2018-11-27 2020-06-04 Zaklady Farmaceutyczne Polpharma S.A Pharmaceutical composition comprising ramipril and indapamide
CN116456979A (zh) * 2020-11-04 2023-07-18 株式会社Lg化学 1-(3-氰基-1-异丙基-吲哚-5-基)吡唑-4-甲酸结晶粒子的制备方法以及包含其的药物组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05000862A (es) * 2002-07-31 2005-04-19 Pharmacia Corp Forma de dosificacion farmaceutica capaz de mantener un perfil de disolucion estable tras el almacenamiento.
DE602006014607D1 (de) * 2005-01-21 2010-07-15 Teva Pharma Stabile pharmazeutische Zusammensetzungen von Zonisamide und Verfahren zur deren Herstellung
JP5330989B2 (ja) * 2007-04-11 2013-10-30 キッセイ薬品工業株式会社 （アザ）インドール誘導体及びその医薬用途
PE20230850A1 (es) * 2020-12-01 2023-05-23 Lg Chemical Ltd Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico y un proceso para su preparacion
TWI903066B (zh) * 2021-04-16 2025-11-01 南韓商Ｌｇ化學股份有限公司 包含１－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸之口服用複合調配物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102574839A (zh) * 2009-10-07 2012-07-11 株式会社Lg生命科学 有效作为黄嘌呤氧化酶抑制剂的新化合物、该化合物的制备方法和含有该化合物的药物组合物
CN103459381A (zh) * 2011-04-06 2013-12-18 株式会社Lg生命科学 1-(3-氰基-1-异丙基-吲哚-5-基)吡唑-4-甲酸晶型及其生产方法
WO2020109319A1 (en) * 2018-11-27 2020-06-04 Zaklady Farmaceutyczne Polpharma S.A Pharmaceutical composition comprising ramipril and indapamide
CN116456979A (zh) * 2020-11-04 2023-07-18 株式会社Lg化学 1-(3-氰基-1-异丙基-吲哚-5-基)吡唑-4-甲酸结晶粒子的制备方法以及包含其的药物组合物

Also Published As

Publication number Publication date
TWI896975B (zh) 2025-09-11
CL2023001215A1 (es) 2023-12-15
CA3197405A1 (en) 2022-06-09
WO2022119269A1 (ko) 2022-06-09
JP7678106B2 (ja) 2025-05-15
EP4257123A1 (en) 2023-10-11
AU2021390901B9 (en) 2024-11-21
KR20220077091A (ko) 2022-06-08
AU2024227367A1 (en) 2024-10-31
JP2023551712A (ja) 2023-12-12
ZA202305156B (en) 2024-09-25
AU2021390901A1 (en) 2023-06-08
TW202600130A (zh) 2026-01-01
AU2021390901B2 (en) 2024-11-07
TW202408496A (zh) 2024-03-01
TWI840721B (zh) 2024-05-01
PE20240222A1 (es) 2024-02-16
AU2021390901A9 (en) 2024-05-23
US20240000751A1 (en) 2024-01-04
EP4257123A4 (en) 2024-05-08
AR124178A1 (es) 2023-02-22
CO2023008265A2 (es) 2023-06-30
TW202228679A (zh) 2022-08-01
MX2023005459A (es) 2023-05-23

Similar Documents

Publication Publication Date Title
AU2024227367A1 (en) Stable oral formulation containing 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid
TWI903066B (zh) 包含１－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸之口服用複合調配物
JP2025039725A (ja) １－（３－シアノ－１－イソプロピル－インドール－５－イル）ピラゾール－４－カルボン酸を含む経口用製剤、およびその製造方法
HK40095726A (zh) 含有1-(3-氰基-1-异丙基-吲哚-5-基)吡唑-4-甲酸的稳定的口服制剂
KR102749903B1 (ko) 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산을 포함하는 경구용 제제
JP7640815B2 (ja) 生理活性ペプチド含有製剤
HK40095918A (zh) 包含1-(3-氰基-1-异丙基-吲哚-5-基)吡唑-4-甲酸的口服制剂及其制备方法
EA049988B1 (ru) Лекарственная форма для перорального применения, содержащая 1-(3-циано-1-изопропил-индол-5-ил)пиразол-4-карбоновую кислоту
HK40102233A (zh) 含有1-(3-氰基-1-异丙基-吲哚-5-基)吡唑-4-甲酸的口服制剂
WO2023107082A1 (en) A film coated tablet of saxagliptin and at least one antioxidant processed with wet granulation
HK40097002A (zh) 含有1-(3-氰基-1-异丙基-吲哚-5-基)吡唑-4-甲酸的口服制剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40095726

Country of ref document: HK

TA01 Transfer of patent application right

Effective date of registration: 20260210

Address after: 201107 Shanghai Minhang District Jin Guang Road 999

Applicant after: Xinda Biotechnology Co.,Ltd.

Country or region after: China

Address before: Seoul, South Kerean

Applicant before: LG CHEM, Ltd.

Country or region before: Republic of Korea

TA01 Transfer of patent application right